We thank Kamholz et al for their comments and agree that the
“pathophysiology of MS may be more complex than previously appreciated.”
In relapsing-remitting MS, the more rapid decline of whole brain N-
acetylaspartate (WBNAA) concentration versus the fractional brain
parenchyma volume (fBPV) suggests that neuronal/axonal dysfunction or loss
(NAA decline) may precede parenchyma loss.
Axonal injury was recently reassessed and found to be a
significant feature in MS in both lesions and normal appearing white
matter (NAWM) [1,2] confirming our findings of widespread NAA loss.
Moreover, it has been shown, [2] using advanced immunohistopathology, that
axonal loss can occur without apparent damage to the surrounding myelin
sheath in both spinal NAWM and lesions.
Although axonal injury can result from chronic demyelination
due to the loss of trophic support from the myelin, it has been reported
that it is also attributed to direct inflammatory neurotoxic attack in
acute lesions or neurodegeneration distant from lesions. [1] In either
case, a significant amount of normal appearing myelin remains intact.
Histopathology has also shown that there is a significant
decrease in the average axonal density (axons per unit area) in both
lesions, ~61%, and NAWM, ~34%, in the corpus callosum and ~57% in the
cervical spine. [3,4] Furthermore, it has also been demonstrated that
there is a correlation between axonal injury and inflammatory mediators
but not demyelination [1,5], which could also lead to NAA loss without
atrophy. NAA loss has also been observed in EAE mouse model axons that are
normally myelinated. [6]
Combined with reactive gliosis, (i.e., axon replacement by astrocytes
[which results in NAA loss but (partially) conserves volume] the above
findings support our observations and assertions that axonal pathology is
not necessarily directly linked to atrophy and myelin loss. As we discuss
in our paper, it is also possible that NAA decrease is due to diffuse
abundant axonal dysfunction (as opposed to loss) which may be partially
recoverable, as reported by De Stefano in the paper cited by Dr. Kamholz
et al.
We concur with Kamholz et al assertion that the number of
possible complex mechanisms does suggest caution when evaluating
relationships between NAA alterations, axonal loss, demyelination, gliosis
and atrophy and that the connections within these pathological processes
may not be straightforward.
References
1. Trapp, B.D, Peterson, J, Ransohoff, R. M, Rudick, R,
Mork, S, and Bo, L. Axonal transection in the lesions of multiple
sclerosis. N Engl J Med 1998;338:278-285.
2. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD.
Neurological disability correlates with spinal cord axonal loss and
reduced N-acetyl aspartate in chronic multiple sclerosis patients. Annals
Neurology 2000;48:893-901
3. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S.
Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain
2000;123:308-317.
4. Evangelou N, Konz D, Esiri MM, Smith S, Palace J,
Matthews PM. Regional axonal loss in the corpus callosum correlates with
cerebral white matter lesion volume and distribution in multiple
sclerosis. Brain 2000;123:1845-9
5. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W.
Acute axonal injury in multiple sclerosis. Correlation with demyelination
and inflammation. Brain 2000; 123:1174-83
6. Fruttiger, M, Montag, D, Schachner, M, and Martini R.
Crucial role for the myelin-associated glycoprotein in the maintenance of
axon-myelin integrity. Eur J Neurosci 1995;7:511-515.